News: Minute Molecular has Merged with Nuclein to Advance its Ultrafast, Low-Cost, Point-of-Care DASH™ PCR Platform.
1800 Sherman Avenue Suite 504 Evanston, IL 60201
Tel: 847-849-0263
David Kelso
Fmr. President and CEO
Dr. David Kelso served as the President and Chief Executive Officer of Minute Molecular Diagnostics, Inc. Dr. Kelso also serves as a Clinical Professor of Biomedical Engineering in the McCormick School of Engineering and Applied Science at Northwestern University. Dr. Kelso has been involved in assay system development for more than 25 years. In 2006, Dr. Kelso’s CIGHT was selected as one of the 43 recipients of the Grand Challenges in Global Health grants awarded by the Bill & Melinda Gates Foundation.
Before joining Northwestern, Professor Kelso developed a number of medical devices for the healthcare industry. He was Chief Scientist at Baxter Healthcare’s Pandex Division from 1986 to 1992 and directed the team of engineers and scientists which developed the a high-throughput, multi-channel blood screening system which detected HIV, hepatitis and other infectious diseases.
In 1981, Professor Kelso founded Pandex Laboratories and served as its president until 1986 when it was acquired by Baxter. The company developed, manufactured and sold analytical systems for biomedical research which included instruments and reagents for performing fluorescence immunoassays, cellular analysis and other research procedures.
Prior to his biotech venture, Professor Kelso was a cofounder of an intrapreneurial group at Abbott Laboratories which developed the TDx system and created the company’s therapeutic drug monitoring business. At Abbott, he also developed the first microprocessor-controlled enzyme immunoassay analyzer, Quantum, leading the industry away from radioactive assays.
Sally McFall, Ph.D. served as the Chief Scientific Officer of Minute Molecular Diagnostics, Inc. She is also the Deputy Director of the Administrative Core and Director of the Technology Development/Refinement Core C-THAN. C-THAN was established in 2018 as part of the Point-of-Care Technologies Research Network created by National Institute of Biomedical Imaging and Bioengineering. Dr. McFall has extensive experience in technology development for low and middle income countries as the Director of Research of the Center for Innovation in Global Health Technologies (CIGHT) in the Department of Biomedical Engineering at Northwestern University. She possesses a broad background in molecular and clinical microbiology and has co-developed point-of-care assays and instruments side by side with CIGHT’s engineering team.
Sally McFall
Fmr. Chief Scientific Officer
Kara Palamountain served as VP of Marketing, Treasurer, and Secretary at Minute Molecular Diagnostics, Inc. Palamountain has worked in diagnostics for over 15 years conducting market entry analysis for point-of-care diagnostics in over a dozen countries (Botswana, Brazil, Cambodia, China, India, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, South Africa, Swaziland, Tanzania, Uganda, Vietnam and Zambia).
Ms. Palamountain is also the President of the Northwestern Global Health Foundation and a Research Associate Professor at the Kellogg School of Management (Kellogg). Prior to her work at the Northwestern Global Health Foundation and at Kellogg, Kara worked as a management consultant in Deloitte's Healthcare practice for over six years (1998-2002; 2004-2006). She received her MBA from Kellogg in 2004 and her BBA from the University of Texas at Austin in 1998.
Kara Palamountain
Fmr. VP Marketing
Walter Narajowski
Walter M. Narajowski served as Chief Operating Officer of Minute Molecular since November, 2020 until the 2023 merger with Nuclein, LLC, where he now serves as a member of the Board of Directors. Mr. Narajowski continues to serve as Partner, LabDx a bio-tech consulting company since 2015. Mr. Narajowski has over 25 years of senior level Medical device and In-Vitro Diagnostic industry experience. Serving as Board member MDXHealth (MDX:EURONEXT) 2014 – 2019. Sr. Vice President & General Manager for Roka BioScience (ROKA:NASDAQ) from 2009 – 2015. President/C.E.O. and Board Member of Pathway Diagnostics a biomarker development and testing company sold to Quest Diagnostics in 2008. Vice President & General Manger of Focus Diagnostics, an Infectious Disease Reference Laboratory and IVD company. Mr. Narajowski spent over 20 years with Abbott Laboratories (NYSE:ABT) in various positions of increasing responsibility vice president and general manager critical care products, general manager of physician office diagnostics and director of research and development with Abbott Diagnostics. Mr. Narajowski received his M.S. in bioengineering from the University of Utah, and his B.S. in electrical engineering from the Illinois Institute of Technology.
Fmr. Chief Operating Officer
Marc has 40 years of extensive leadership experience in the creation and commercialization of complex medical products for a worldwide market. These products are being used today in hospitals, laboratories, clinics, physician offices and by patients at home around the world.
Marc Minkus
Fmr. VP Operations